Design Therapeutics, Inc.
$13.16
▲
2%
2026-04-21 06:29:01
www.designtx.com
NMS: DSGN
Explore Design Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$809.14 M
Current Price
$13.16
52W High / Low
$13.5 / $3.1
Stock P/E
—
Book Value
$3.52
Dividend Yield
—
ROCE
-37.28%
ROE
-30.7%
Face Value
—
EPS
$-1.22
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
54
Beta
1.58
Debt / Equity
0.72
Current Ratio
17.14
Quick Ratio
17.14
Forward P/E
-7.09
Price / Sales
—
Enterprise Value
$531.62 M
EV / EBITDA
-6.78
EV / Revenue
—
Rating
None
Target Price
$14.67
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Prelude Therapeutics Incorporated | $4.51 | — | $279.73 M | — | -118.39% | -99.45% | $5.54 / $0.72 | $0.83 |
| 2. | Zura Bio Limited | $5.37 | — | $491.42 M | — | -74.11% | -52.49% | $7.44 / $0.98 | $1.38 |
| 3. | Impact BioMedical Inc. | $0.68 | — | $67.48 M | — | -26.29% | -1.04% | $1.95 / $0.36 | $0.12 |
| 4. | Larimar Therapeutics, Inc. | $4.81 | — | $499.68 M | — | -212.84% | -1.33% | $6.42 / $1.73 | $0.94 |
| 5. | Q32 Bio Inc. | $6.65 | 3.26 | $97.29 M | — | 33.52% | 1.25% | $8.04 / $1.34 | $3.27 |
| 6. | HCW Biologics Inc. | $0.41 | — | $2.94 M | — | -4764.31% | -897.37% | $17.8 / $0.25 | $-0.8 |
| 7. | BioAtla, Inc. | $5.69 | — | $7.61 M | — | 732.7% | 543.76% | $71.5 / $3.92 | $-0.6 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -18.17 M | -19.31 M | -21.57 M | -20.42 M | -16.69 M | — |
| Net Profit | -16 M | -17 M | -19.08 M | -17.71 M | -13.65 M | — |
| EPS in Rs | -0.26 | -0.28 | -0.31 | -0.29 | -0.22 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -79.47 M | -62.38 M | -78.19 M | -67.59 M |
| Net Profit | -69.79 M | -49.59 M | -66.86 M | -63.31 M |
| EPS in Rs | -1.13 | -0.8 | -1.08 | -1.03 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 226.2 M | 252.09 M | 289.64 M | 341.14 M |
| Total Liabilities | 13.7 M | 10 M | 11.96 M | 13.83 M |
| Equity | 212.5 M | 242.1 M | 277.69 M | 327.31 M |
| Current Assets | 223.78 M | 248.04 M | 284.58 M | 335.12 M |
| Current Liabilities | 13.05 M | 8.46 M | 9.62 M | 10.78 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -54.36 M | -43.1 M | -58.56 M | -51.32 M |
| Investing CF | 22.91 M | 43.95 M | 52.54 M | -220.99 M |
| Financing CF | 25.74 M | 0.51 M | 0.72 M | 0.23 M |
| Free CF | -54.55 M | -43.45 M | -58.82 M | -52.23 M |
| Capex | -0.19 M | -0.34 M | -0.26 M | -0.92 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 25.84% | -5.61% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.